Why the study?
Patients with cancer are less frequently covered by cardiovascular preventive measures, making parallel cardiological diagnostics and treatment alongside anticancer therapy necessary.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Early cardiological surveillance and optimal pharmacotherapy, including the addition of an SGLT2 inhibitor, can enable the safe administration of potentially cardiotoxic cancer therapy in patients with recent myocardial infarction and HFrEF.
Patients diagnosed with cancer are less frequently covered by preventive measures for cardiovascular diseases. The frequent co-occurrence of these diseases makes it necessary to apply parallel diagnostics and cardiological treatment with anti-cancer therapy. Case report: We present a case of a 73-year-old former smoker with hyperlipidemia, type 2 diabetes, and arterial hypertension, after a partial right nephrectomy in 2005 due to kidney cancer, diagnosed with SARS-COV-2 infection in April 2022. Follow-up chest imaging showed a 20 mm focal lesion in the left lung further classified as a small cell neuroendocrine carcinoma. Unexpectedly the patient was hospitalized for ST-segment elevation inferior left ventricular (LV) myocardial infarction treated successfully with coronary angioplasty, however heart failure (HF) with reduced left ventricle ejection fraction was diagnosed. One month later patient required another hospitalization due to the HF decompensation and cardiological treatment was optimized with flozin addition to the standard HF therapy. After cardiological approval chemotherapy was initiated with the cisplatinum-etoposide regimen and continued for 6 months without HF decompensation and significant deterioration of renal function. After that, the patient underwent radical radiotherapy. Follow-up chest computed tomography scans showed regression of the neoplastic lesion. Conclusions: Coincidence of newly recognized cancer and infection might contribute and provoke serious cardiological events . To reduce the risk of cardiovascular complications, early periodic cardiological surveillance and optimal pharmacotherapy are required.
No takes yet. Share an insight, caveat, or question.
Iwański et al. (2023) conducted a case report in Co-occurrence of COVID-19, lung cancer, STEMI, and heart failure (n=1). Parallel cardiological and anti-cancer therapy was evaluated.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: